April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Suramab Strongly Inhibits Lymphangiogenesis and Angiogenesis in the Cornea
Author Affiliations & Notes
  • E. S. Lopez
    Research Area, Universidad Austral, Capital Federal, Argentina
  • O. J. Croxatto
    Servicio de Patologìa Ocular, Fundación Oftalmológica Argentina "Jorge Malbran", Capital Federal, Argentina
  • J. E. Gallo
    Ophthalmology, Hospital Universitario Austral, Pilar, Argentina
  • Footnotes
    Commercial Relationships  E.S. Lopez, None; O.J. Croxatto, None; J.E. Gallo, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5694. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. S. Lopez, O. J. Croxatto, J. E. Gallo; Suramab Strongly Inhibits Lymphangiogenesis and Angiogenesis in the Cornea. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5694.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To analyze the effect of Suramab and Bevacizumab to inhibit angiogenesis and lymphangiogenesis in the cornea.

Methods: : Corneal neovascularization was induced in three groups of nine White New Zealand rabbits, applying a filter paper disc soaked in 1M Na (OH) on the central cornea. Group 1 was treated after injury with intravenous Suramab (S) at a doses equivalent to 3mg/kg of Bevacizumab and 10mg/kg of Suramin, Group 2 was treated with intravenous Bevacizumab (B) at a doses of 3mg./kg, and Group 3 did not receive any treatment. Corneal sections were inmunohistochemically analysed with primary antibodies Lyve-1 (lymphatic vascular endothelial marker) and Pecam as an endothelial marker. The jimage program was used to calculate hematological and lymphatic vascularized areas.

Results: : The area of immunoreactivity for blood vessels was smaller in treated groups (S: 0.76mm²; B: 0.95 mm²) compared to controls (3.4 mm²) . The area stained with Lyve-1 was significantly reduced in suramab (0.56 mm²) group than that found in Bevacizumab (1.62mm²) and control animals (2.8mm²) (p<0.05).

Conclusions: : Intravenous Suramab and Bevacizumab inhibit angiogenesis and lymphangiogenesis in the cornea, although the effect of Suramab is stronger.

Keywords: cornea: clinical science • neovascularization • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.